Protocol Ledger

Academic / Institutional Sponsor · Consolidated Sponsor Hub

Guangdong Association of Clinical Trials: Clinical Trials & FDA Approval Profile

Guangdong Association of Clinical Trials (Global / Institutional) sponsors 19 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 13 active protocols (7 recruiting now), 1 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)0.0%
Median Closed Enrollment vs National (145 pts)60 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Guangdong Association of Clinical Trials
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)19
Active Pipeline (Recruiting Now)13 (7)
Completed vs Stopped Early1 / 0 (0.0%)
Median Closed Actual Enrollment60 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Guangdong Association of Clinical Trials
Hospital Research SiteLocationShared Protocols
Guangdong Provincial People's HospitalGuangzhou3
The Second Affiliated Hospital of Nanchang UniversityNanchang, Jiangxi2

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Guangdong Association of Clinical Trials
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05536505Adjuvant Treatment Based on MRD for EGFR Mutant NSCLCPhase IIRECRUITING
NCT07198841IBI351 Plus Cetuximab β in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C MutationPhase IIRECRUITING
NCT04768075Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLCPhase IIICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Guangdong Association of Clinical Trials Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI